News Release

Rapid high-dose buprenorphine treatment strategy reduces opioid withdrawal in individuals using fentanyl

Peer-Reviewed Publication


Buprenorphine is a medication approved for pain and opioid dependence. New findings published in The American Journal on Addictions indicate that a transmucosal dose (which dissolves in the mouth) of buprenorphine followed by an injection of extended-release buprenorphine (BUP‐XR) may be an effective treatment for individuals with opioid use disorder who use fentanyl.

The results come from a recent secondary analysis of an open-label study in which 24 participants received a single 4 mg dose of transmucosal buprenorphine followed by an injection of 300 mg of BUP‐XR after approximately 1 hour.

Clinical Opioid Withdrawal Scale scores dropped significantly after treatment.

“Fentanyl and 20 other synthetic opioids are the leading cause of overdose deaths in 21 the United States and rapid induction to BUP‐XR injection may be an important potential treatment option for this at‐risk population,” the authors wrote.

URL upon publication:


Additional Information
The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout,

About the Journal
The American Journal on Addictions is the official journal of the American Academy of Addiction Psychiatry, and provides a forum for the dissemination of information in the extensive field of addiction, including topics ranging from codependence to genetics, epidemiology to dual diagnostics, etiology to neuroscience, and much more.

About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Follow us on FacebookTwitterLinkedIn and Instagram.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.